Cizzle Biotechnology Holdings PLC (GB:CIZ)
LSE:CIZ
Want to see GB:CIZ full AI Analyst Report?
Top Page
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Select Model
Select Model
Rating:49Neutral
Price Target:
3.50 p
▲(125.81% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (no revenue, sustained losses and cash burn, and equity turning negative). Technicals provide some support due to a strong uptrend, but overbought momentum signals add risk. Valuation remains challenged because profitability is negative and no dividend support is available.
Positive Factors
Clear strategic focus on lung cancer diagnostics
A focused business model targeting blood-based early lung cancer diagnostics aligns with a durable unmet medical need. Specialization can concentrate R&D, streamline clinical validation, and position the company to capture value from screening and diagnostic markets as adoption grows.
Negative Factors
Pre-revenue with persistent operating losses
The absence of revenue and consistent operating losses mean the company relies on external funding to sustain R&D. Over a multi-month horizon, persistent burn without commercialization increases dilution risk and raises execution pressure to reach revenue-generating milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Clear strategic focus on lung cancer diagnostics
A focused business model targeting blood-based early lung cancer diagnostics aligns with a durable unmet medical need. Specialization can concentrate R&D, streamline clinical validation, and position the company to capture value from screening and diagnostic markets as adoption grows.
Read all positive factors
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£12.11M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue GrowthN/A
EPS Growth69.64%
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechno...
How the Company Makes Money
null...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -753.00K | 0.00 | 0.00 | -963.00K | -3.96M |
| Net Income | -691.00K | -2.17K | -1.72K | -910.00K | -3.92M |
Balance Sheet | |||||
| Total Assets | 245.00K | 492.00K | 1.69M | 2.79M | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 116.00K | 387.00K | 1.56M | 478.00K | 875.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 585.00K | 410.00K | 186.00K | 145.00K | 218.00K |
| Stockholders Equity | -340.00K | 82.00K | 1.51M | 2.64M | 937.00K |
Cash Flow | |||||
| Free Cash Flow | -498.00K | -358.00K | -639.00K | -872.00K | -1.21M |
| Operating Cash Flow | -496.00K | -358.00K | -639.00K | -872.00K | -1.01M |
| Investing Cash Flow | -2.00K | 0.00 | 0.00 | -120.00K | -154.00K |
| Financing Cash Flow | 249.00K | 579.00K | 305.00K | 595.00K | 2.03M |
Cizzle Biotechnology Holdings PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.94M | -0.88 | -53.79% | ― | ― | 85.56% | |
49 Neutral | £12.11M | -8.89 | -433.59% | ― | ― | 69.64% | |
43 Neutral | £5.94M | -2.61 | -2.42% | ― | 102.28% | 95.58% | |
42 Neutral | £4.07M | -0.40 | -115.97% | ― | -87.82% | -704.65% | |
42 Neutral | £4.44M | -1.83 | -153.80% | ― | ― | 90.91% | |
41 Neutral | £1.41M | -0.64 | ― | ― | 418.49% | 45.35% |
* Healthcare Sector Average
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.85
1.20
72.73%
GB:TCF
Evgen Pharma
0.23
>-0.01
-4.17%
GB:FUM
Futura Medical
0.70
-7.30
-91.25%
GB:NFX
Nuformix Plc
0.17
0.06
57.41%
GB:OPTI
OptiBiotix Health
5.75
-12.50
-68.49%
GB:VAL
ValiRx plc
0.19
-0.36
-65.45%
Cizzle Biotechnology Holdings PLC Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cizzle Ties Executive Incentives to Lung Cancer Test Milestones Amid Ongoing Salary Waivers
Positive
May 7, 2026
Cizzle Biotechnology Holdings has introduced a new performance-based management incentive plan and conditionally granted share options to directors, subject to shareholder approval, in lieu of salary increases that have been waived since its 2021 ...
Private Placements and FinancingRegulatory Filings and Compliance
Cizzle Biotechnology Converts £400,000 of Loan Notes Into New Equity
Positive
May 6, 2026
Cizzle Biotechnology has received a notice from investor Frazer Lang to convert £400,000 of existing convertible loan notes into 28,571,429 new ordinary shares at 1.4 pence per share, strengthening its equity base and reducing outstanding deb...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Cizzle Biotechnology Publishes 2025 Annual Report and Financial Statements
Neutral
Apr 30, 2026
Cizzle Biotechnology Holdings has published its Annual Report and Financial Statements for the year ended 31 December 2025. The document, detailing the company’s financial performance and activities over the period, is now available online t...
Business Operations and StrategyPrivate Placements and Financing
Cizzle Biotechnology Secures £250,000 Convertible Funding To Back Lung Cancer Test Rollout
Positive
Apr 2, 2026
Cizzle Biotechnology has arranged a new unsecured funding facility of up to £250,000 in convertible loan notes with existing investor Frazer Lang, extending previously agreed note programmes that now total £400,000 already drawn. The new...
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Secures Extra Royalties as U.S. Lung Cancer Test Nears Launch
Positive
Feb 23, 2026
Cizzle Biotechnology reported progress toward the U.S. commercial launch of its CIZ1B blood test for early lung cancer detection, as North American partner Cizzle Bio Inc. nears completion of validation work with Omni Health Diagnostics in Texas a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.